. 2012 May 11;2(3):e000914. doi: 10.1136/bmjopen-2012-000914

Table 2.

Use of antidopaminergic drugs and acute pancreatitis among 6161 cases and 61 637 control subjects from 2006 to 2008 in Sweden

Antidopaminergic drug use. Time before index date	Antiemetic/anxiolytic antidopaminergic drugs^*			Other antidopaminergic drugs^†
Antidopaminergic drug use. Time before index date	Crude^‡, OR (95% CI)	Model 1^§, OR (95% CI)	Model 2^¶, OR (95% CI)	Crude^‡, OR (95% CI)	Model 1^§, OR (95% CI)	Model 2^¶, OR (95% CI)
No use	1	1	1	1	1	1
Current (0–114 days)	1.9 (1.4 to 2.6)	1.4 (1.0 to 1.9)	0.9 (0.6 to 1.2)	1.4 (1.1 to 1.6)	1.1 (0.9 to 1.4)	0.8 (0.6 to 0.9)
Recent (115–180 days)	3.1 (1.6 to 5.7)	2.5 (1.3 to 4.9)	1.6 (0.8 to 3.0)	1.8 (0.9 to 3.4)	1.4 (0.7 to 2.8)	1.2 (0.6 to 2.4)
Past (6–12 months)	2.3 (1.4 to 3.9)	1.8 (1.0 to 3.0)	1.1 (0.6 to 1.9)	2.3 (1.5 to 3.7)	1.9 (1.2 to 3.1)	1.5 (0.9 to 2.4)
Former (>12 months)	3.2 (2.3 to 4.5)	2.1 (1.5 to 3.0)	1.5 (1.0 to 2.1)	1.5 (0.9 to 2.4)	1.1 (0.7 to 1.8)	1.0 (0.6 to 1.6)

No use of antidopaminergic drugs is the reference category.

Dixyrazine, levomepromazine, melperone and prochlorperazine.

^†

Fluphenazine, perphenazine, flupenthixole, thioridazine, chlorpromazine, haloperidol, pimozide, ziprasidone, aripiprazole, quetiapine, risperidone, paliperidone, clozapine and olanzapine.

^‡

Adjusted for age and sex.

^§

Adjusted for history of alcohol-related comorbidity.

^¶

Adjusted for history of alcohol-related diagnoses or drugs for alcoholism, chronic obstructive lung disease, ischaemic heart disease, obesity, diabetes, opioid use, gallstone disease, educational level, marital status and number of concomitant medications.